

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Mirikizumab for treating moderately to severely active Crohn's disease ID6244

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
CompanyEli Lilly (mirikizumab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Bladder and Bowel Community Bowel Cancer UK	Board of Community Health Councils in Wales
Colostomy UK Crahm's and Colitical UK	British National Formulary Core Overlity Commissions
Crohn's and Colitis UK	Care Quality Commission
GUTS UK	Department of Health, Social Services
IA: Ileostomy and Internal Pouch	and Public Safety for Northern Ireland
Group	Healthcare Improvement Scotland
 South Asian Health Foundation 	Medicines and Healthcare products
Specialised Healthcare Alliance	Regulatory Agency
	National Association of Primary Care
Healthcare professional groups	National Pharmacy Association
Association of Coloproctology of Great	NHS Confederation
Britain and Ireland	Scottish Medicines Consortium
Association of Surgeons of Great	Welsh Government
Britain and Ireland	Welsh Health Specialised Services
British Geriatrics Society	Committee
British Society of Gastroenterology	
Primary Care Society for	Possible comparator companies
Gastroenterology	AbbVie (adalimumab, risankizumab,
Royal College of Anaesthetists	upadacitinib)
Royal College of General Practitioners	Amgen (adalimumab)
Royal College of Nursing	Biogen - Biosimilars (adalimumab,
Royal College of Pathologists	infliximab)
Royal College of Physicians	Celltrion Healthcare UK (adalimumab,
Royal College of Surgeons of England	infliximab)
 Royal College of Surgeons of England Royal Pharmaceutical Society 	Fresenius Kabi (adalimumab)
	 Johnson & Johnson Innovative
Royal Society of Medicine Ill Clinical Pharmacy Association	Medicine (ustekinumab)
UK Clinical Pharmacy Association	Merck Sharp & Dohme (infliximab)
Othoro	· · · · · · · · · · · · · · · · · · ·
Others 10 11 11 11 10 110	Pfizer (infliximab) Sandaz (adalimumab infliximab)
Department of Health and Social Care	Sandoz (adalimumab, infliximab) Talvada LIV (condalimumab, infliximab)
NHS England	Takeda UK (vedolizumab)

Provisional stakeholder list for the evaluation of mirikizumab for treating moderately to severely active Crohn's disease ID6244



Consultees	Commentators (no right to submit or appeal)
	Relevant research groups Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Cochrane UK Genomics England MRC Clinical Trials Unit National Institute for Health Research
	Associated Public Health groupPublic Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of mirikizumab for treating moderately to severely active Crohn's disease ID6244

Issue date: January 2024